Amplia Therapeutics (ATX) AI Stock Analysis

• Market Cap: AU$61.57M
• Dividend Yield: N/A
• Average Volume (3M): 525.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: N/A
• EPS Growth: 26.64%
• Country: AU
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 513,071,660
• 10 Day Avg. Volume: 444,673
• 30 Day Avg. Volume: 525,217
• PEG Ratio: 0.42
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 5.68
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: AU$0.12 ▼(-17.14% Downside)
• Action: Reiterated Date: 01/22/26
• Date: Action: Reiterated 01/22/26

The score is held down primarily by ongoing losses and weak cash generation, despite a relatively stable, low-leverage balance sheet. Technically, the stock is trading below key longer-term moving averages with only mild momentum. Valuation is also constrained by negative earnings and the absence of dividend yield.

Positive Factors

Conservative Balance Sheet / Low Leverage

The company’s low debt-to-equity stance and healthy equity ratio provide a durable financial buffer, lowering bankruptcy risk and giving management flexibility to fund clinical programs, pursue partnerships, or raise capital on better terms over the coming months.

Very High Gross Margins

Consistently >90% gross margins indicate an efficient cost base for any revenue-related activity. For a development-stage biotech, this suggests attractive economics for licensing or future commercialization and helps preserve value as clinical programs progress.

Focused Oncology Pipeline

A clear strategic focus on FAK inhibitors with narmafotinib (AMP945) targeting solid tumors aligns with long-term oncology trends toward targeted therapies. This concentration improves strategic clarity and partnership appeal, supporting durable value creation as trials advance.

Negative Factors

Negative Operating and Free Cash Flow

Persistent negative operating and free cash flows force reliance on external financing, partnerships, or dilutive capital raises. This constrains autonomy over trial timelines, increases financing risk, and may delay development milestones over the next several months.

Ongoing Losses and Negative Margins

Ongoing negative net, EBIT and EBITDA margins show the company is not yet generating returns from its equity base. Persistent losses reduce internal funding capacity, heighten dependency on external capital, and make positive clinical readouts essential to alter the financial trajectory.

Very Limited Internal Operating Scale

A reported headcount of one indicates minimal internal operational capacity and heavy dependence on CROs, contractors, or partners for trials and regulatory work. This elevates execution risk, can slow timelines, and may increase outsourcing costs over the medium term.

Amplia Therapeutics Business Overview & Revenue Model

Company Description

Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.

How the Company Makes Money

Amplia Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company's revenue model includes funding from grants and research partnerships, which support the clinical development of its therapies. Additionally, Amplia may enter into licensing agreements or partnerships with larger pharmaceutical companies, allowing them to share in the development costs and potential profits from successful drug candidates. Revenue can also be derived from milestone payments and royalties based on sales once products are commercialized. Furthermore, the company may attract investment through equity financing to support its ongoing research and development efforts.

Amplia Therapeutics Financial Statement Overview

Summary

Mixed financials typical of a development-stage biotech: very strong gross margins and some revenue growth, but continued losses (negative net/EBIT/EBITDA margins). Balance sheet leverage is low with a healthy equity base, yet return on equity is negative. Cash flow remains a key weakness with negative operating and free cash flow.

Income Statement

Amplia Therapeutics shows a mixed performance in its income statement. The company has a strong gross profit margin, consistently above 90%, indicating efficient cost management. However, the net profit margin is negative, reflecting ongoing losses, which is common in the biotechnology industry due to high R&D expenses. Revenue growth is positive, but the company has not yet achieved profitability, as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet of Amplia Therapeutics is relatively stable, with a low debt-to-equity ratio, suggesting conservative leverage. However, the return on equity is negative, indicating that the company is not generating profits from its equity base. The equity ratio is healthy, showing a strong equity position relative to total assets, which provides a buffer against financial instability.

Cash Flow

Amplia Therapeutics faces challenges in its cash flow statement. The company has negative operating and free cash flows, which are typical for biotech firms in the development stage. The free cash flow to net income ratio is close to 1, indicating that cash outflows are closely aligned with reported losses. Despite a significant increase in free cash flow growth, the overall cash flow position remains weak.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.38M	3.78M	4.45M	1.19M	1.98M	1.53M
Gross Profit	2.20M	3.57M	4.01M	1.12M	1.98M	1.53M
EBITDA	-10.75M	-6.78M	-4.48M	-7.26M	-3.64M	-3.81M
Net Income	-7.93M	-6.57M	-4.50M	-6.24M	-3.64M	-2.28M
Balance Sheet
Total Assets	44.54M	22.94M	14.85M	18.68M	24.48M	10.88M
Cash, Cash Equivalents and Short-Term Investments	29.16M	10.86M	3.39M	9.26M	14.61M	1.85M
Total Debt	381.42K	13.89K	1.59M	2.27M	2.10M	0.00
Total Liabilities	1.61M	1.91M	3.43M	2.85M	2.64M	539.13K
Stockholders Equity	42.93M	21.02M	11.42M	15.84M	21.85M	10.34M
Cash Flow
Free Cash Flow	-13.39M	-6.89M	-5.13M	-5.31M	-4.42M	-2.92M
Operating Cash Flow	-13.36M	-6.89M	-5.13M	-5.29M	-4.40M	-2.92M
Investing Cash Flow	-81.65K	-2.07K	-2.23K	-58.42K	-26.64K	-5.35K
Financing Cash Flow	37.99M	14.32M	-772.98K	-84.22K	17.19M	3.66M

Amplia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Negative. The current price of 0.14 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.14, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ATX.

Amplia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NC6	48 Neutral	AU$24.16M	-9.61	-1651.76%	―	-100.00%	2.86%
CMB	48 Neutral	AU$11.25M	-2.68	-166.70%	―	―	―
AVE	48 Neutral	AU$36.73M	-7.14	-143.71%	―	306.88%	―
ATX	43 Neutral	AU$61.57M	-5.97	-27.39%	―	―	26.64%
NOX	43 Neutral	AU$19.97M	-3.46	-157.93%	―	―	-36.89%
1AD	37 Underperform	AU$10.20M	-2.38	-628.72%	―	―	31.87%

Amplia Therapeutics Corporate Events

Amplia Therapeutics Reappoints Experienced CFO to Support Biotech Growth

Amplia Therapeutics has appointed Hamish George as its Chief Financial Officer, effective 25 February 2026, marking his return to the role after previously serving as CFO from October 2021 and succeeding fellow Bio101 Financial Advisory director Tim Luscombe. The move underscores continuity in financial leadership at the ASX-listed biotech, with management highlighting George’s extensive life sciences finance experience as supportive of Amplia’s ongoing development programs in cancer and fibrosis.

The change in CFO, while not altering Amplia’s strategic direction, is likely to provide stability and specialised financial oversight as the company advances its FAK inhibitor pipeline in competitive oncology and fibrosis markets. For stakeholders, the reappointment of an experienced and previously proven finance chief signals an emphasis on governance, capital management and operational consistency during a critical phase of clinical and corporate development.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial

Amplia Therapeutics has opened two new U.S. clinical sites at the University of California, Irvine and The Cleveland Clinic for its AMPLICITY trial, which evaluates lead FAK inhibitor narmafotinib in combination with modified FOLFIRINOX in newly diagnosed advanced pancreatic cancer patients. These centres join two existing Australian sites, with three more U.S. sites expected to come online shortly, significantly broadening the recruitment base and strengthening Amplia’s clinical and investor presence in the U.S. market.

The AMPLICITY trial, run under an open IND with the FDA and aligned with Project Optimus principles, will assess safety, tolerability, pharmacokinetics and efficacy across two parts to determine the optimal daily dose of narmafotinib for future studies. The expansion builds on earlier ACCENT trial data, where narmafotinib combined with gemcitabine and Abraxane achieved a higher confirmed response rate and encouraging progression-free survival, underscoring the drug’s potential to enhance standard chemotherapy in pancreatic cancer and raising the stakes for stakeholders watching Amplia’s progress in this high‑need indication.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture

Amplia Therapeutics has completed the first large-scale, GMP-compliant manufacture of narmafotinib, producing about 13 kilograms of active pharmaceutical ingredient and successfully transitioning production from an R&D setting to a commercial-ready environment. The scale-up, achieved in collaboration with a contract development and manufacturing partner, has generated cost efficiencies and ensures sufficient drug supply to support Amplia’s ongoing and planned pancreatic cancer trials and other studies, marking a key step toward Phase 3 readiness and strengthening the company’s clinical development pipeline and future registrational strategy.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI

Amplia Therapeutics has reported updated interim data from its Phase 2a ACCENT trial in metastatic pancreatic cancer, presented at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial, which evaluates narmafotinib in combination with standard chemotherapies gemcitabine and Abraxane, shows a progression-free survival of 7.7 months versus 5.5 months for chemotherapy alone and an overall response rate of 35%, rising to 42% including unconfirmed responses, while maintaining a safety profile comparable to chemotherapy alone. Management says the ASCO GI presentation reinforces Amplia’s positioning among leading oncology developers and highlights the potential of narmafotinib to improve outcomes in advanced pancreatic cancer, complementing its broader clinical strategy that includes the newly opened AMPLICITY trial combining narmafotinib with FOLFIRINOX.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Deepens Next & Bio Collaboration to Test Narmafotinib–kRAS Combo in Pancreatic Cancer

Amplia Therapeutics has entered a second phase of its preclinical research collaboration with Korean drug screening specialist Next & Bio to further investigate the effects of its FAK inhibitor narmafotinib in combination with experimental kRAS inhibitors on patient-derived pancreatic cancer cells. The extension follows encouraging initial data showing narmafotinib’s activity against kRAS-mutant pancreatic cancer models, and the partners will now explore potential synergistic effects with kRAS inhibitors, a new class of drugs under development for several solid tumours. Amplia sees this next stage as an opportunity to strengthen its scientific case for combination therapies in hard-to-treat pancreatic cancer, enhance the clinical and commercial prospects of narmafotinib and potentially broaden partnering opportunities, while Next & Bio leverages its advanced patient-derived cell platform to support the development of new treatment options in an area of high unmet medical need.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

Amplia Therapeutics Reports Positive ACCENT Trial Results for Pancreatic Cancer

Amplia Therapeutics announced a positive development in its ACCENT trial for metastatic pancreatic cancer, where its FAK inhibitor narmafotinib, combined with gemcitabine and nab-paclitaxel, achieved a 35% objective response rate. This result surpasses the 23% response rate of the benchmark MPACT trial, indicating a significant advancement in treatment efficacy. The data will be presented at the Life Sciences Virtual Investor Forum, highlighting Amplia’s potential impact on cancer treatment and its strategic positioning in the pharmaceutical industry.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.